MK-0657 (CERC-301) (Figure 14), a selective GluN2B antagonist, at 4–8 mg/day orally administered to patients for 12 days for treatment-resistant depression (TRD) disclosed a remarkable recovery from depressive symptoms when compared with placebo, and without major unfavorable side effects [176]. The gene discussed is GRIN2B; the disease is treatment resistant depression.